21763-00-8

Basic information

• Product Name: (1-Bromo-3-chloropropyl)benzene
• Synonyms: (1-Bromo-3-chloropropyl)benzene
• CAS NO: 21763-00-8
• Molecular Formula: C₉H₁₀BrCl
• Molecular Weight: 233.5327
• Mol File: 21763-00-8.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 118-120 °C(Press: 20 Torr)
• Appearance: /
• Density: 1.423±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerated.
• CAS DataBase Reference: (1-Bromo-3-chloropropyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: (1-Bromo-3-chloropropyl)benzene(21763-00-8)
• EPA Substance Registry System: (1-Bromo-3-chloropropyl)benzene(21763-00-8)

Safety Data

• Hazardous Substances Data: 21763-00-8(Hazardous Substances Data)

Usage

General Description

(1-Bromo-3-chloropropyl)benzene, also known as 1-(3-Bromo-3-chloropropyl)benzene, is a chemical compound with the molecular formula C9H10BrCl. It is a colorless to pale yellow liquid with a faint, sweet odor. (1-Bromo-3-chloropropyl)benzene is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also utilized in the production of polymers and as a solvent in various chemical processes. Additionally, 1-(3-Bromo-3-chloropropyl)benzene is considered to have low toxicity and has not been found to cause significant environmental hazards. However, it should be handled with care and in accordance with proper safety protocols due to its potential to cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 104-52-9 phenylpropyl chloride 
• 94-36-0 dibenzoyl peroxide 
• 936-59-4 3-chloropropiophenone 
• 18776-12-0 3-chloro-1-phenyl-propan-1-ol 

Downstream Products

• 385436-87-3 [4-(3-chloro-1-phenyl-propoxy)-phenyl]-phenyl-methanone 
• 21763-01-9 1-phenyl-1-phenoxy-3-chloropropane 
• 81347-68-4 1-chloro-3-phenyl-3-(4-trifluoromethylphenoxy)propane 
• 75384-66-6 1-phenyl-1-(p-trifluoromethylphenoxy)propylchloride 
• 53179-07-0 nisoxetine 
• 17382-10-4 1,1-dimethyl 2-phenylcyclobutane-1,1-dicarboxylate 
• 56161-70-7 N-methyl-3-phenoxy-3-phenyl-1-propylamine 
• 56225-81-1 N,N-dimethyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)-1-propylamine 
• 54910-89-3 FLUOXETINE 
• 57226-60-5 3-chloro-1-(o-methoxyphenoxy)propylbenzene 
• 1356708-17-2 5,5'-diallyl-2-methoxy-2'-[3-(methylamino)-1-phenylpropoxy]biphenyl hydrochloride 
• 1356708-21-8 5,5'-diallyl-2-methoxy-2'-[3-(methylamino)-1-phenylpropoxy]biphenyl 

Relevant articles and documents

Sulphide as a leaving group: Highly stereoselective bromination of alkyl phenyl sulphides

A conceptionally novel nucleophilic substitution approach to synthetically important alkyl bromides is presented. Using molecular bromine (Br2), readily available secondary benzyl and tertiary alkyl phenyl sulphides are converted into the corresponding bromides under exceptionally mild, acid- and base-free reaction conditions. This simple transformation allows the isolation of elimination sensitive benzylic β-bromo carbonyl and nitrile compounds in mostly high yields and purities. Remarkably, protic functionalities such as acids and alcohols are tolerated. Enantioenriched benzylic β-sulphido esters, readily prepared by asymmetric sulpha-Michael addition, produce the corresponding inverted bromides with high stereoselectivities, approaching complete enantiospecificity at -40 °C. Significantly, the reported benzylic β-bromo esters can be stored without racemisation for prolonged periods at -20 °C. Their synthetic potential was demonstrated by the one-pot preparation of γ-azido alcohol (S)-5 in 90% ee. NMR studies revealed an initial formation of a sulphide bromine adduct, which in turn is in equilibrium with a postulated dibromosulphurane intermediate that undergoes C-Br bond formation.

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Molecular basis for selective serotonin reuptake inhibition by the antidepressant agent fluoxetine (Prozac)

Inhibitors of the serotonin transporter (SERT) are widely used antidepressant agents, but the structural mechanism for inhibitory activity and selectivity over the closely related norepinephrine transporter (NET) is not well understood. Here we use a combination of chemical, biological, and computational methods to decipher the molecular basis for high-affinity recognition in SERT and selectivity over NET for the prototypical antidepressant drug fluoxetine (Prozac; Eli Lilly, Indianapolis, IN). We show that fluoxetine binds within the central substrate site of human SERT, in agreement with recent X-ray crystal structures of LeuBAT, an engineered monoamine-like version of the bacterial amino acid transporter LeuT. However, the binding orientation of fluoxetine is reversed in our experimentally supported model comparedwith the LeuBAT structures, emphasizing the need for careful experimental verification when extrapolating findings from crystal structures of bacterial transporters to human relatives. We find that the selectivity of fluoxetine and nisoxetine, a NET selective structural congener of fluoxetine, is controlled by residues in different regions of the transporters, indicating a complex mechanism for selective recognition of structurally similar compounds in SERT and NET. Our findings add important new information on the molecular basis for SERT/NET selectivity of antidepressants, and provide the first assessment of the potential of LeuBAT as a model system for antidepressant binding in human transporters, which is essential for future structure-based drug development of antidepressant drugs with fine-tuned transporter selectivity. Copyright